These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 32989921)

  • 21. Multiplex Epstein-Barr virus BALF2 genotyping detects high-risk variants in plasma for population screening of nasopharyngeal carcinoma.
    Miller JA; Sahoo MK; Yamamoto F; Huang C; Wang H; Zehnder JL; Le QT; Pinsky BA
    Mol Cancer; 2022 Jul; 21(1):154. PubMed ID: 35902864
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical characteristics and prognostic value of pre-retreatment plasma epstein-barr virus DNA in locoregional recurrent nasopharyngeal carcinoma.
    Liu MZ; Fang SG; Huang W; Wang HY; Tian YM; Huang RD; Sun Z; Zhao C; Lu TX; Huang Y; Han F
    Cancer Med; 2019 Aug; 8(10):4633-4643. PubMed ID: 31268626
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study.
    Liu SL; Sun XS; Li XY; Tang LQ; Chen QY; Lin HX; Liang YJ; Yan JJ; Lin C; Guo SS; Liu LT; Li Y; Xie HJ; Tang QN; Liang H; Guo L; Mai HQ
    Cancer Commun (Lond); 2019 Mar; 39(1):14. PubMed ID: 30925939
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma Epstein-Barr virus DNA as a biomarker for nasopharyngeal carcinoma.
    Chan KC
    Chin J Cancer; 2014 Dec; 33(12):598-603. PubMed ID: 25418194
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Proposed modifications and incorporation of plasma Epstein-Barr virus DNA improve the TNM staging system for Epstein-Barr virus-related nasopharyngeal carcinoma.
    Guo R; Tang LL; Mao YP; Du XJ; Chen L; Zhang ZC; Liu LZ; Tian L; Luo XT; Xie YB; Ren J; Sun Y; Ma J
    Cancer; 2019 Jan; 125(1):79-89. PubMed ID: 30351466
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Assessment of detection assays of Epstein-Barr viral Rta-IgG, VCA-IgA, EA-IgA and Epstein-Barr viral DNA at different clinical stages in the diagnosis of nasopharyngeal carcinoma].
    Luo YL; Chen H; Peng SG; Lin JH; Huang PY
    Zhonghua Yi Xue Za Zhi; 2013 Nov; 93(44):3516-9. PubMed ID: 24521892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic values of the integrated model incorporating the volume of metastatic regional cervical lymph node and pretreatment serum Epstein-Barr virus DNA copy number in predicting distant metastasis in patients with N1 nasopharyngeal carcinoma.
    Yao JJ; Zhou GQ; Wang YQ; Wang SY; Zhang WJ; Jin YN; Zhang F; Li L; Liu LZ; Cheng ZB; Ma J; Qi ZY; Sun Y
    Chin J Cancer; 2017 Dec; 36(1):98. PubMed ID: 29284539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complementary determination of Epstein-Barr virus DNA load and serum markers for nasopharyngeal carcinoma screening and early detection in individuals at risk in Tunisia.
    Baizig NM; Morand P; Seigneurin JM; Boussen H; Fourati A; Gritli S; Oueslati Z; Touati S; Gamoudi A; Ben Abdallah M; El May M; El May A
    Eur Arch Otorhinolaryngol; 2012 Mar; 269(3):1005-11. PubMed ID: 21805179
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic value of plasma Epstein-Barr virus DNA level during posttreatment follow-up in the patients with nasopharyngeal carcinoma having undergone intensity-modulated radiotherapy.
    Li WF; Zhang Y; Huang XB; Du XJ; Tang LL; Chen L; Peng H; Guo R; Sun Y; Ma J
    Chin J Cancer; 2017 Nov; 36(1):87. PubMed ID: 29116021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Epstein-Barr virus microRNAs BART7-3p and BART13-3p as novel biomarkers in nasopharyngeal carcinoma.
    Lu T; Guo Q; Lin K; Chen H; Chen Y; Xu Y; Lin C; Su Y; Chen Y; Chen M; Zheng Y; Ye Y; Lin S; Zong J; Pan J
    Cancer Sci; 2020 May; 111(5):1711-1723. PubMed ID: 32155300
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein-Barr virus mir-bart1-5p detection via nasopharyngeal brush sampling is effective for diagnosing nasopharyngeal carcinoma.
    Zheng XH; Lu LX; Cui C; Chen MY; Li XZ; Jia WH
    Oncotarget; 2016 Jan; 7(4):4972-80. PubMed ID: 26701721
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epstein-Barr virus and human papillomavirus serum antibodies define the viral status of nasopharyngeal carcinoma in a low endemic country.
    Simon J; Schroeder L; Ingarfield K; Diehl S; Werner J; Brenner N; Liu Z; Pawlita M; Pring M; Butt J; Ness A; Waterboer T
    Int J Cancer; 2020 Jul; 147(2):461-471. PubMed ID: 32279316
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of Epstein-Barr virus viral load in patients with T1-T2 nasopharyngeal cancer.
    Mazurek AM; Wygoda A; Rutkowski T; Olbryt M; Pietrowska M; Celejewska A; Składowski K; Widłak P
    J Med Virol; 2020 Mar; 92(3):348-355. PubMed ID: 31608452
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Utility of Epstein-Barr Virus DNA in Nasopharynx Swabs as a Reflex Test to Triage Seropositive Individuals in Nasopharyngeal Carcinoma Screening Programs.
    Chen GH; Liu Z; Yu KJ; Coghill AE; Chen XX; Xie SH; Lin DF; Huang QH; Lu YQ; Ling W; Lin CY; Lu ZJ; Fan YY; Tang LQ; Sampson JN; Li H; King AD; Middeldorp JM; Hildesheim A; Cao SM
    Clin Chem; 2022 Jul; 68(7):953-962. PubMed ID: 35325087
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Role of Epstein-Barr Virus DNA Load and Serology as Screening Tools for Nasopharyngeal Carcinoma.
    Tay JK; Chan SH; Lim CM; Siow CH; Goh HL; Loh KS
    Otolaryngol Head Neck Surg; 2016 Aug; 155(2):274-80. PubMed ID: 27143706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genome-Wide Analysis of 18 Epstein-Barr Viruses Isolated from Primary Nasopharyngeal Carcinoma Biopsy Specimens.
    Tu C; Zeng Z; Qi P; Li X; Yu Z; Guo C; Xiong F; Xiang B; Zhou M; Gong Z; Liao Q; Yu J; He Y; Zhang W; Li X; Li Y; Li G; Xiong W
    J Virol; 2017 Sep; 91(17):. PubMed ID: 28637758
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Validation of a Highly Sensitive qPCR Assay for the Detection of Plasma Cell-Free Epstein-Barr Virus DNA in Nasopharyngeal Carcinoma Diagnosis.
    Anh VNQ; Van Ba N; Anh DT; Ung ND; Hiep NH; Ly VT; Hang DTT; Sy BT; Chinh HD; Ky LM; Phong VT; Luu NK; Trung NT; Son HA; Van Luong H; Thuan ND; Tung NT; Tho HH
    Cancer Control; 2020; 27(3):1073274820944286. PubMed ID: 32726136
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hopkins criteria for residual disease assessment after definitive radiotherapy in nasopharyngeal carcinoma.
    Liu Y; Long W; Wang G; Yang Y; Liu B; Fan W
    Cancer Med; 2020 Feb; 9(4):1328-1334. PubMed ID: 31875356
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Assay of Epstein-Barr virus in nasopharyngeal tissues and serum of patients with nasopharyngeal carcinoma].
    Li XM; Yang CZ; Chen PJ; Su ZL; Song Y
    Lin Chuang Er Bi Yan Hou Ke Za Zhi; 2000 Sep; 14(9):400-1. PubMed ID: 12563909
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.